Mineralys Therapeutics, Inc. Common Stock (MLYS) is a publicly traded Healthcare sector company. As of May 20, 2026, MLYS trades at $28.45 with a market cap of $2.18B and a P/E ratio of -12.11. MLYS moved +9.30% today. Year to date, MLYS is -20.27%; over the trailing twelve months it is +76.58%. Its 52-week range spans $8.24 to $47.65. Analyst consensus is strong buy with an average price target of $51.17. Rallies surfaces MLYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Mineralys Therapeutics, Inc. Common Stock (MLYS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. MLYS moved +9.30% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $28.45 |
| Market Cap | $2.18B |
| P/E Ratio | -12.11 |
| EPS | $-2.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $47.65 |
| 52-Week Low | $8.24 |
| Volume | 4.05M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-154.65M |
| Gross Margin | 0.00% |
8 analysts cover MLYS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $51.17.